Severe hypoglycemia during pneumocystis pneumonia treatment associated with trimethoprim–sulfamethoxazole use in a patient on peritoneal dialysis

Abstract

Background

Trimethoprim–sulfamethoxazole (TMP/SMX) is an essential antimicrobial agent for treating pneumocystis pneumonia (PCP). Furthermore, the risk of hypoglycemia is increased with the co-administration of sulfonylurea due to the presence of the same sulfanilamide structural group in SMX and sulfonylurea. However, hypoglycemia caused by a single administration of TMP/SMX is a rare adverse reaction, and not many cases have been reported. Renal failure is a risk factor for hypoglycemia with single TMP/SMX administration.

Case presentation

A 54-year-old Japanese woman on peritoneal dialysis (PD) for 10 years was admitted to our hospital for the suspicion of PCP. She underwent immunosuppressive treatment with oral prednisolone (3 mg/day) and a subcutaneous injection of adalimumab (40 mg) every 2 weeks for rheumatoid arthritis. We initiated the administration of a low-to-moderate dose of TMP/SMX (TMP equivalent to TMP/SMX, approximately 8 mg/kg/day) in the patient, considering that she was on PD. At 10 days after administration, the patient became unconscious, and blood test results showed that her blood glucose level was low (15 mg/dL). Unlike hypoglycemia, her serum insulin levels were abnormally high (69.4 μU/mL) at that time. Glucose injection was used for correcting the hypoglycemia, but it was refractory. Highly concentrated glucose infusion was needed to maintain her blood glucose level normal. Her serum insulin level was confirmed to have returned to normal (4.0 μU/mL) at 9 days after completing the TMP/SMX treatment.

Conclusions

We suspected that the refractory hypoglycemia in this case was caused by high levels of insulin secretion due to the accumulation of TMP/SMX. One of the risk factors in this patient was the low excretion rate of TMP/SMX into the PD fluid. Although hypoglycemia is a rare complication of TMP/SMX, we should consider this risk during TMP/SMX use in patients, especially those on PD.

Background

Trimethoprim–sulfamethoxazole (TMP/SMX) is a combination of two antimicrobial agents: TMP and SMX. TMP/SMX is used for the prophylaxis of and as a first-line treatment for pneumocystis pneumonia (PCP), which is caused by Pneumocystis jirovecii in human immunodeficiency virus (HIV) patients and non-HIV immunocompromised hosts [1]. PCP is a fatal disease, especially in non-HIV patients. The mortality rate is much higher in non-HIV patients (50%) than in HIV patients (6.7%) [2]. For appropriate treatment, an adequate amount of TMP/SMX is needed. TMP/SMX is an antibiotic that needs dose adjustment in accordance with the patient’s renal function.

Hypoglycemia is a rare adverse reaction of TMP/SMX administration. However, co-administration with sulfonylurea increases the risk of hypoglycemia by 6.6 times [3]. Nunnari et al. reported two cases of TMP/SMX-associated severe hypoglycemia, which was caused by a sulfonylurea-like effect of TMP/SMX. They suggested that the risk of hypoglycemia should be considered, especially when prolonged treatment and high dosage is used. SMX is considered to have a sulfonylurea-like effect of increasing endogenous insulin secretion because insulin levels are elevated after administration [4]. The presence of the same sulfanilamide structural group in the two agents (Fig. 1) may be an explanation for this effect. Kenteu et al. reported an acute glycemic effect of TMP/SMX. They performed a 75-g oral glucose tolerance test with or without oral TMP/SMX administration in healthy adults. None of the volunteers experienced hypoglycemia, but their glycemic response was reduced after TMP/SMX administration [5]. This result clinically supports the stimulation of insulin secretion effect of SMX.

Fig. 1

Structural similarities between sulfamethoxazole (a) and the basic structure of sulfonylurea (b). The sulfonamide group is encircled by the dotted line. R¹ and R² are different in each sulfonylurea

Strevel et al. reviewed 13 cases of TMP/SMX-induced hypoglycemia and reported that renal insufficiency is the most prevalent predisposing risk factor (93%) [6]. Only few cases of hypoglycemia caused by the single administration of TMP/SMX have been reported in Japan [7, 8] since the first Japanese case was reported in 1987 [7]. Cases of patients on peritoneal dialysis (PD) have not yet been reported in Japan.

An ideal TMP/SMX dose for treating a PCP patient on PD has not been described. The risk of hypoglycemia during treatment in a patient on PD should be considered.

Case presentation

A 54-year-old Japanese woman visited our hospital with the chief complaint of worsening cough and persistent mild fiver. She had been maintained on PD due to end-stage renal disease (ESRD) for 10 years. She had anuria and a history of rheumatoid arthritis (RA), for which she underwent immunosuppressive treatment with daily oral prednisolone (3 mg) and a subcutaneous injection of adalimumab (40 mg) every 2 weeks. She also had a history of hypertension, chronic heart failure, and osteoporosis. Her other maintenance medications were lansoprazole (10 mg), nifedipine (40 mg), doxazosin (2 mg), carvedilol (10 mg), ferric citrate hydrate (1000 mg), lanthanum carbonate hydrate (750 mg), and calcitriol (0.30 μg). Hypoglycemic agents and insulin analogs were not used. She did not have any surgical history except for PD catheter insertion.

Her body weight was 42.6 kg; height, 150.1 cm; and body mass index, 18.9 kg/m². She had a mild fever (37.4 °C), with blood pressure of 154/81 mmHg and tachycardia (heart rate = 100 beats/min). She had tachypnea (respiratory rate = 20 breaths/min), and her SpO₂ in room air was 99%. On physical examination, a systolic murmur was heard at the apex, but lung auscultation revealed unremarkable findings. Mild ulnar deviations and hallux valgus due to RA were seen, with no pitting edema on the lower extremities. Computed tomography (CT) of the chest showed bilateral ground-glass opacities (Fig 2). Her blood counts were as follows: white blood cells, 8200/μL; red blood cells, 352 × 10⁴/μL; hemoglobin, 11.1 g/dL; and platelets, 26.4 × 10⁴/μL. Her blood glucose was 125 mg/dL; blood urea nitrogen, 58.9 mg/dL; and creatinine, 8.96 mg/dL. Her hemoglobin A1c was 4.5%. C-reactive protein levels were elevated by 7.23 mg/dL, and β-D-glucan levels were also high (23.3 pg/mL). HIV antibody was negative. P. jirovecii DNA polymerase chain reaction of sputum was positive. Bronchoscopy was considered but could not be performed due to the patient’s refusal. According to these results, a clinical diagnosis of PCP was made. Cytomegalovirus (CMV) pneumonia, tuberculosis, and other fungal infections were differential diagnoses, but CMV antigenemia, T-SPOT, Candida antigen, Aspergillus antigen, and Cryptococcus neoformans antigen were negative.

Fig. 2

Computed tomography images taken on the day of admission. Bilateral ground-glass opacities were seen. Pleural effusions, lymphadenopathy, and nodules were not seen

We started treatment with a low-to-moderate dose of TMP/SMX (TMP equivalent to TMP/SMX, approximately 8 mg/kg/day), considering that the patient was on PD and was anuric. At 10 days after TMP/SMX administration, the patient suddenly became unconscious after complaining of palpitations and sweating. She was perspiring markedly and did not respond to orders. At that time, her vital signs were as follows: body temperature, 37.0 °C; blood pressure, 140/70 mmHg; heart rate, 112 beats/min; and respiratory rate, 24 breaths/min; SpO₂ in room air was 99%. Blood glucose levels were immediately checked, and results indicated that the levels were low (20 mg/dL). Glucose injection (10 g/shot) was used for correcting the hypoglycemia. The glucose levels were temporarily elevated to normal, but they soon went down. Even after 22 glucose injections (220 g of glucose in total) and glucose infusions (75 g of glucose over 18 h), the severe hypoglycemia (15 mg/dL) persisted (Fig. 3). We measured the serum insulin and C-peptide levels during severe hypoglycemia, and results indicated levels of 69.4 μU/mL and 13.10 ng/mL, respectively. Insulin autoimmune syndrome was ruled out because insulin antibody was negative. Adrenal insufficiency was considered because the patient’s cortisol level was relatively low at that time (Table 1), but she was taking oral prednisolone daily, and it could not explain the hyperinsulinemia and persistent severe hypoglycemia that could not be corrected by glucose injections and infusions. Insulinoma was clinically ruled out because the patient had no previous history of hypoglycemia, and the blood glucose levels were unresponsive; in addition, there were no nodules and masses in the pancreas, according to CT images.

Fig. 3

Severe hypoglycemia observed from days 11 p.m. to 12 a.m. Hypoglycemia was unresponsive to glucose injections; 50% glucose from one ampule (20 cc: 10 g of glucose) was injected the when the blood glucose level was <70 mg/dL. Hypoglycemia persisted even after 22 glucose injections were administered with continuous glucose infusion. *Blood glucose level is lower than the minimum measurable level

Table 1 Laboratory data on days 11 and 23 (blood samples were taken early morning)

We suspected TMP/SMX-induced severe hypoglycemia. Because the patient needed to continue PCP treatment for 14 days, we inserted a central venous catheter in her right neck to infuse highly concentrated glucose (50% glucose) and maintain normal blood glucose levels. Using a glucose infusion at 20 g/h led to an improvement in the hypoglycemia, but the patient exhibited asymptomatic hypoglycemia at several instances. We decreased the glucose infusion to 10 g/h on day 17 (the day that PCP was successfully treated for 14 days with TMP/SMX administration), but the patient had hypoglycemia during early morning. We monitored her blood glucose levels using real-time continuous glucose monitoring (RT-CGM, THE MINIMED^® 620G SYSTEM, Medtronic Japan Co., Ltd., Tokyo, Japan) and corrected her hypoglycemia by adjusting the amount of glucose infusion (Fig. 4). On day 22, glucose infusion was stopped, and hypoglycemia was no longer detected. After the patient was stabilized, we measured her serum insulin levels, which had returned to normal (4.0 μU/mL on day 23). This result supported a definitive diagnosis of TMP/SMX-associated severe hypoglycemia. On day 23, an adrenocorticotropic hormone stimulation test—measuring serum cortisol levels immediately before as well as 30 and 60 min after the intravenous injection of 250 μg of cosyntropin—was performed, but the results indicated unresponsiveness (data not shown). This finding is compatible with tertiary adrenal insufficiency due to long-term steroid use.

Fig. 4

RT-CGM results from days 16 to 21. The patient exhibited hypoglycemia again on the morning of day 17 (boxed by the dotted line, magnified on the lower right). The amount of glucose infusion was reduced by gradually adjusting the injection rate of 50% glucose fluid. *Time is written as military time (commonly used in Japan). RT-CGM: real-time continuous glucose monitoring, TMP/SMX: trimethoprim–sulfamethoxazole

We added a low-dose of TMP/SMX (TMP equivalent to TMP/SMX, 40 mg) in this patient for prophylaxis against PCP because she had a high risk of recurrent P. jirovecii infection. After taking a low dose of TMP/SMX, the patient did not become hypoglycemic and was discharged on day 36 without any medical complications.

Discussion

TMP/SMX is well-absorbed through oral administration and has a good bioavailability. Accumulation of the drug should be considered in a patient with compromised renal function due to the prolongation of its half-life [9]. The structural similarity of SMX with sulfonylurea may result in pancreatic insulin secretion, particularly at higher doses and in patients with renal impairment [6]. We reviewed previously reported 22 cases of TMP/SMX-associated hypoglycemia [4, 6,7,8, 10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25] (Table 2). In most of the cases (77%), patients had renal impairment (serum creatinine > 1.1 mg/dL and/or on renal replacement therapy). A moderate-to-high dose of TMP/SMX (≥ 1600 mg of SMX/ day) was used for treating PCP in 45% of the cases. We could find two cases of HD patients [11, 14] and one case of PD patient [16]. Although serum insulin levels were not available for all the cases, in most cases, hyperinsulinemia was observed despite low serum blood glucose levels. We considered that hyperinsulinemia was caused by insulin secretion due to the sulfonylurea-like effect of SMX, and renal impairment and high-dose TMP/SMX use were two major predisposing factors for TMP/SMX-induced hypoglycemia. The kidneys have an important role in the clearance and degradation of circulating insulin. It is estimated that 30–80% of insulin entering the kidneys is removed [26]. Although conclusive evidence regarding the contribution of the kidneys to total body gluconeogenesis is not available, the kidneys contribute to the maintenance of glucose homeostasis to some extent [27]. Similar to our case, we should consider a prolonged insulin effect and low ability to maintain glucose homeostasis in ESRD patients without urine output.

Table 2 Previously reported 22 cases of trimethoprim-sulfamethoxazole-induced hypoglycemia and the present case

We suspected that the persistent hypoglycemia in the present case was caused by the accumulation of SMX in this patient because of PD without urine output. Walker et al. reported the pharmacokinetics of TMP/SMX in 10 adult patients on continuous ambulatory PD. The patients were given one dose of TMP (320 mg) and SMX (1600 mg) orally, intravenously, and intraperitoneally on separate occasions. At 24 h after administration, < 3% of TMP and < 6% of SMX were excreted in the dialysate, regardless of the route of administration [28]. To achieve prompt recovery, hemodialysis (HD) might be a better choice because HD has a higher clearance of SMX compared with CAPD. Nissenson et al. reported the pharmacokinetics of intravenous TMP/SMX during HD. A total of 16 patients with ESRD received a single ampule of TMP/SMX (containing 800 mg of SMX) at 45 min prior to HD, and 57% of the administered SMX was removed during the 4-h HD [29].

In this case, long-term steroid use was also a risk for prolonged hypoglycemia due to tertiary adrenal insufficiency, because steroids suppress the secretion of corticotropin-releasing hormone from the hypothalamus [30]. Senanayake et al. reported a case of hypoglycemia caused by a prophylactic dose of TMP/SMX in a patient with eosinophilic granulomatosis with polyangiitis using prednisolone for immunosuppressive therapy, although the patient was without renal impairment [24]. Symptoms of hypoglycemia were ameliorated by increasing the prednisolone dosage. In our case, increasing the steroid dosage could have been considered to reduce the amount of glucose infusions because the patient had anuria. Volume overload due to infusion becomes a serious problem in PD patients because the rehydration amount is limited in these patients.

There was a possibility that the glucose in the PD fluid acted as a buffer against hypoglycemia to some extent in this case. The patient used icodextrin PD fluid during the night time (from 10 p.m. to 9 a.m., 2000 mL) and 1.5% glucose bicarbonate/lactate-buffered PD fluid from 9 a.m. to 10 p.m. (three cycles of 2000 mL). Icodextrin use might be a part of the reason why hypoglycemia was seen mainly from midnight to early morning in this case.

Although RT-CGM is usually used for monitoring the glucose levels of patients with type 1 diabetes [31], it was effective in this case to detect asymptomatic hypoglycemia earlier, and it enabled the patient to monitor glucose levels more appropriately compared with the self-monitoring of blood glucose. Lower dose TMP/SMX for prophylaxis against PCP was acceptable in this patient, along with the careful monitoring of blood glucose levels after the detachment of RT-CGM during hospitalization.

Conclusions

We encountered a complicated case of severe hypoglycemia associated with TMP/SMX use in a patient on PD. To our knowledge, this is the first Japanese case of hypoglycemia in a patient on PD caused by TMP/SMX use alone. Hypoglycemia was persistent and refractory, and glucose infusion was needed for almost a week even after PCP treatment was completed to maintain the blood glucose at normal levels. Although hypoglycemia is a rare adverse reaction when TMP/SMX is used in isolation, the risk of hypoglycemia should be considered when using higher than average doses of TMP/SMX in patients with renal failure, especially in those on PD, because of the lower excretion rate of the drug into PD fluids. Routine blood glucose monitoring might be recommended in selected cases.